Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | METAP2 | P50579 | 2/20 | 0.45 |
| ▸ | PLAU | P00749 | 1/20 | 0.45 |
| ▸ | NCF1 | P14598 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8342585 | 0.82 | GAA (0.55) | GAAMETAP2PLAUNCF1BRD4 | |
| SCHEMBL27856321 | 0.79 | CYP3A4 (0.52) | CYP19A1CYP11B1CYP11B2CYP3A4CYP1A2 | |
| SCHEMBL10066877 | 0.75 | CYP3A4 (0.54) | IDO1GAACYP19A1CYP11B1CYP11B2 | |
| SCHEMBL28614447 | 0.74 | CYP3A4 (0.52) | IDO1GAACYP19A1CYP11B1CYP11B2 | |
| SCHEMBL26666217 | 0.73 | NPC1 (0.59) | IDO1CYP19A1CYP11B1CYP11B2CYP3A4 | |
| SCHEMBL4453814 | 0.73 | GAA (0.50) | GAAMETAP2PLAUNCF1BRD4 | |
| SCHEMBL8342753 | 0.72 | GAA (0.49) | GAAMETAP2PLAUNCF1BRD4 | |
| SCHEMBL4448982 | 0.72 | GAA (0.49) | GAAMETAP2PLAUNCF1BRD4 | |
| SCHEMBL8344232 | 0.71 | METAP2 (0.51) | GAAMETAP2PLAUNCF1BRD4 | |
| SCHEMBL16923125 | 0.71 | CYP3A4 (0.48) | IDO1GAACYP19A1CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0005794-B1 | A PROCESS FOR THE STEREO-SPECIFIC OR STEREO-SELECTIVE PREPARATION OF IMIDAZOLYL-OXIME ETHER DERIVATIVES AND IMIDAZOLYL-OXIME DERIVATIVES | SIEGFRIED AKTIENGESELLSCHAFT (CH) | 1983-01-05 | — | — | EP | claimed |
| US-11701374-B1 | 8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression | SIERRA SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11701374-B1 | 8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression | SIERRA SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-9302993-B2 | 8-hydroxy quinoline derivatives | PRANA BIOTECHNOLOGY LIMITED (AU) | 2016-04-05 | — | — | US | disclosed |
| US-9302993-B2 | 8-hydroxy quinoline derivatives | PRANA BIOTECHNOLOGY LIMITED (AU) | 2016-04-05 | — | — | US | disclosed |
| US-20150335635-A1 | 8-HYDROXY QUINOLINE DERIVATIVES | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-11-26 | — | — | US | disclosed |
| US-20150335635-A1 | 8-HYDROXY QUINOLINE DERIVATIVES | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-11-26 | — | — | US | disclosed |
| US-9169211-B2 | 8-hydroxy quinoline derivatives | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-10-27 | — | — | US | disclosed |
| US-9169211-B2 | 8-hydroxy quinoline derivatives | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-10-27 | — | — | US | disclosed |
| US-20150094334-A1 | 8-HYDROXY QUINOLINE DERIVATIVES | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-04-02 | — | — | US | disclosed |
| US-8163760-B2 | Use of pyridopyrimidine compounds in the treatment of gliomas | PRANA BIOTECHNOLOGY LIMITED (AU) | 2012-04-24 | — | — | US | disclosed |
| US-8163760-B2 | Use of pyridopyrimidine compounds in the treatment of gliomas | PRANA BIOTECHNOLOGY LIMITED (AU) | 2012-04-24 | — | — | US | disclosed |
| US-20100069393-A1 | METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-03-18 | — | — | US | disclosed |
| US-20100069393-A1 | METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-03-18 | — | — | US | disclosed |
| US-7619091-B2 | Treating nervous system disorders such as mild cognitive impairment, Alzheimer's disease or dementia associated with Down syndrome; e.g. use of 5,7-dichloro-8-hydroxy-2-(2-pyridyl)-quinoline (PBT 1052) | PRANA BIOTECHNOLOGY LIMITED (AU) | 2009-11-17 | — | — | US | disclosed |
| US-7619091-B2 | Treating nervous system disorders such as mild cognitive impairment, Alzheimer's disease or dementia associated with Down syndrome; e.g. use of 5,7-dichloro-8-hydroxy-2-(2-pyridyl)-quinoline (PBT 1052) | PRANA BIOTECHNOLOGY LIMITED (AU) | 2009-11-17 | — | — | US | disclosed |
| US-20080161353-A1 | 8-Hydroxy quinoline derivatives | PRANA BIOTECHNOLOGY LIMITED (AU) | 2008-07-03 | — | — | US | disclosed |
| US-20080161353-A1 | 8-Hydroxy quinoline derivatives | PRANA BIOTECHNOLOGY LIMITED (AU) | 2008-07-03 | — | — | US | disclosed |
| WO-2007147217-A1 | METHOD OF TREATMENT OF GLIOMA BRAIN TUMOUR | PRANA BIOTECHNOLOGY LIMITED (AU) | 2007-12-27 | — | — | WO | disclosed |
| WO-2004007461-A1 | 8-HYDROXY QUINOLINE DERIVATIVES | PRANA BIOTECHNOLOGY LIMITED (AU) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069393-A1 | METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME | MGMT, DHFR, IDH2 | IDO1 1867/4885GAA 819/4885METAP2 370/4885 |
| US-20150335635-A1 | 8-HYDROXY QUINOLINE DERIVATIVES | PARK7, COQ8A, NLN | IDO1 1644/4885GAA 117/4885METAP2 1832/4885 |
| US-20080161353-A1 | 8-Hydroxy quinoline derivatives | PARK7, COQ8A, NLN | IDO1 1644/4885GAA 117/4885METAP2 1832/4885 |
| US-11701374-B1 | 8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression | TERT, TERF2, RNGTT | IDO1 4289/4885GAA 1030/4885METAP2 1330/4885 |
| US-20150094334-A1 | 8-HYDROXY QUINOLINE DERIVATIVES | PARK7, COQ8A, NLN | IDO1 1644/4885GAA 117/4885METAP2 1832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.